CRISPR / Cas14a coupled TdT electrochemical biosensor and preparation method and application thereof

Through CRISPR/Cas14a-coupled TdT electrochemical biosensor, the low specificity and expensive equipment of exosome detection in early diagnosis of nasopharyngeal carcinoma are solved, and high sensitivity and high specificity of exosome detection from nasopharyngeal carcinoma is achieved , laying the theoretical foundation for the early diagnosis of nasopharyngeal carcinoma.

CN118914330AInactive Publication Date: 2024-11-08SHENZHEN BAOAN DISTRICT FUYONG PEOPLES HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411263509.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the early diagnosis of nasopharyngeal carcinoma, the exosome detection has problems such as low specificity, expensive equipment and complex operation, and it is difficult to achieve high sensitivity and high specificity of nasopharyngeal carcinoma-derived exosome detection.

Method used

Electrochemical biosensors using CRISPR/Cas14a-coupled TdT, magnetic nanoparticles modified by streptavidin, biotin-modified aptamers, base-complementary probes, terminal deoxynucleotide transferases and deoxythoracic thorax Components such as glycoside triphosphate are constructed to construct the CRISPR-Cas14 system and combine it with gold electrodes to achieve high specificity and high sensitivity detection of exosomes from nasopharyngeal carcinoma.

Benefits of technology

It realizes high specificity and high sensitivity detection of exosomes from nasopharyngeal carcinoma, simplifies operation, reduces equipment requirements, improves the sensitivity and specificity of the detection, and provides a theoretical basis for the early diagnosis of nasopharyngeal carcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914330A_ABST
    Figure CN118914330A_ABST
Patent Text Reader

Abstract

The invention discloses a CRISPR / Cas14a coupled TdT electrochemical biosensor as well as a preparation method and application thereof, and belongs to the field of medical nano materials. The electrochemical biosensor comprises a gold electrode and a CRISPR-Cas14 system, wherein the CRISPR-Cas14 system is constructed by magnetic nanoparticles modified by streptavidin, an aptamer modified by biotin, a probe complementary with a basic group of the aptamer, terminal deoxynucleotidyl transferase, deoxythymidine triphosphate, sgRNA (small guide ribonucleic acid) and Cas14a. An electrochemical signal is amplified by coupling TdT with Cas14a, the problems that a traditional method for detecting exosomes is poor in selectivity, expensive instruments and equipment are needed, sensitivity is insufficient and the like are solved, high-specificity and high-sensitivity detection of nasopharyngeal carcinoma source exosomes is achieved, and a theoretical foundation is laid for early diagnosis of nasopharyngeal carcinoma.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Cited By

  • Electrochemical biosensor based on TdT-Cas12a reaction system and HaeIII enzyme and Alzheimer's biomarker detection method

    CN121453876A